Get all your news in one place.
100's of premium titles.
One app.
Start reading
Medical Daily
Medical Daily
Health
Dorothy Brooks

AstraZeneca Seeks FDA Approval for Savolitinib Plus Tagrisso in Lung Cancer That Resists Tagrisso Through MET Changes

AstraZeneca has asked the FDA to approve a two-pill combination for people with EGFR-mutated lung cancer whose tumors keep growing on Tagrisso because of changes involving a protein called MET. HUTCHMED announced the U.S. New Drug Application on Sept. 28 for savolitinib, sold in China as Orpathys, plus Tagrisso (osimertinib). The combination is not approved in the United States.

The filing matters to patients who face a hard turn in their care. Tagrisso is a standard daily pill for EGFR-mutated lung cancer, but tumors often find ways around it. When that happens, the usual next step is chemotherapy.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.